Den europeiske union - norsk - EMA (European Medicines Agency)

virbac s.a. - renset rp-45 felv-konvolutt antigen - inaktivert viral vaksiner - katter - aktiv immunisering av katter fra åtte ukers alder mot feline leukemi for forebygging av vedvarende viraemi og kliniske tegn på den relaterte sykdommen.

Den europeiske union - norsk - EMA (European Medicines Agency)

virbac s.a. - renset p45 felv-konvolutt antigen - inaktivert viral vaksiner, feline leukemi virus, immunologicals for felidae, - katter - aktiv immunisering av katter fra åtte ukers alder mot feline leukemi for forebygging av vedvarende viraemi og kliniske tegn på den relaterte sykdommen.

Den europeiske union - norsk - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influensavirusoverflateantigener (hemagglutinin og neuraminidase) av stamme a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaksiner - aktiv immunisering mot h5n1 subtype av influensa a-virus. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Den europeiske union - norsk - EMA (European Medicines Agency)

virbac s.a. - purified p45 feline leukaemia virus envelope antigen, live feline calicivirus (strain f9), live feline viral rhinotracheitis virus (strain f2), live feline panleucopenia virus - live feline panleucopenia virus / parvovirus + live feline rhinotracheitis virus + live feline calicivirus + inaktivert feline leukemi virus - katter - for aktiv immunisering av katter fra åtte ukers alder mot: feline calicivirosis for å redusere kliniske tegn. feline viral rhinotracheitt for å redusere kliniske tegn og viral utskillelse. feline panleukopeni for å hindre leukopeni og redusere kliniske tegn. felin leukemi for å forhindre vedvarende viraemi og kliniske tegn på den relaterte sykdommen. immunitetens begynnelse: 3 uker etter primærvaksinasjonen for panleukopeni og leukemi-komponentene, og 4 uker etter primærvaksinering for kalicivirus- og rhinotrakeittviruskomponentene. immunitetsvarighet: ett år etter primærvaksinering for alle komponenter.

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals for felidae, - katter - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - katter - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Norge - norsk - Statens legemiddelverk

fresenius kabi norge as - halden - soyaolje, renset / glukosemonohydrat / alanin / arginin / aspartinsyre / glutaminsyre / glysin / histidin / isoleucin / leucin / lysinhydroklorid / metionin / fenylalanin / prolin / serin / treonin / tryptofan / tyrosin / valin / kalsiumkloriddihydrat / natriumglyserofosfat / magnesiumsulfatheptahydrat / kaliumklorid / natriumacetattrihydrat - infusjonsvæske, emulsjon

Norge - norsk - Statens legemiddelverk

fresenius kabi norge as - halden - soyaolje, renset - infusjonsvæske, emulsjon - 200 mg/ ml

Norge - norsk - Statens legemiddelverk

fresenius kabi norge as - halden - soyaolje, renset / glukosemonohydrat / alanin / arginin / aspartinsyre / glutaminsyre / glysin / histidin / isoleucin / leucin / lysinhydroklorid / metionin / fenylalanin / prolin / serin / treonin / tryptofan / tyrosin / valin / kalsiumkloriddihydrat / natriumglyserofosfat / magnesiumsulfatheptahydrat / kaliumklorid / natriumacetattrihydrat - infusjonsvæske, emulsjon

Norge - norsk - Statens legemiddelverk

b. braun melsungen ag - glukosemonohydrat / natriumdihydrogenfosfatdihydrat / sinkacetatdihydrat / soyaolje, renset / triglyserider av middels kjedelengde / isoleucin / leucin / lysinhydroklorid / metionin / fenylalanin / treonin / tryptofan / valin / arginin / histidinhydrokloridmonohydrat / alanin / aspartinsyre / glutaminsyre / glysin / prolin / serin / natriumhydroksid / natriumklorid / natriumacetattrihydrat / kaliumacetat / magnesiumacetattetrahydrat / kalsiumkloriddihydrat - infusjonsvæske, emulsjon - 64 mg/ ml / 0.936 mg/ ml / 0.0052 mg/ ml / 20 mg/ ml / 20 mg/ ml / 1.872 mg/ ml / 2.504 mg/ ml / 1.818 mg/ ml / 1.568 mg/ ml / 2.808 mg/ ml / 1.456 mg/ ml / 0.456 mg/ ml / 2.08 mg/ ml / 2.16 mg/ ml / 1 mg/ ml / 3.88 mg/ ml / 1.2 mg/ ml / 2.8 mg/ ml / 1.32 mg/ ml / 2.72 mg/ ml / 2.4 mg/ ml / 0.64 mg/ ml / 0.865 mg/ ml / 0.435 mg/ ml / 2.354 mg/ ml / 0.515 mg/ ml / 0.353 mg/ ml